All News

Data presented at the ongoing European Cancer Congress has identified a different epigenetic profile in the tumors of younger colorectal cancer patients, information that can help improve treatment options in this population.

The technology was approved by FDA in June and unveiled at the Scientific Sessions of the American Diabetes Association.

Eighty-six million US adults are at high risk of developing type 2 diabetes. Without prevention, there will be a drastic increase in the number of Americans who will develop type 2 diabetes.

Medicare beneficiaries undergoing dialysis who reach the Part D coverage gap have increased out-of-pocket spending, increased medical service utilization and costs, and increased mortality, according to a new study.

A new report from The Commonwealth Fund has found similarities between premium costs for marketplace enrollees and those with employer plans. According to Are Marketplace Plans Affordable?, 60% of marketplace enrollees and 55% of individuals with employer plans pay either nothing or less than $125 a month for individual coverage.

Addiction is a national scourge. Cognitive Technologies are needed to deal with this very expensive illness.

Top managed care stories this week include the follow up to the National Academy of Medicine's groundbreaking "To Err Is Human" report, findings on the sharp increase in deductibles, and discussing costs in cancer care.

More than $100 million in Affordable Care Act funding is being awarded to 17 national, regional, and state hospital associations and health system organizations to assist efforts to reduce hospital-acquired conditions and readmissions.

The pharmaceutical industry's largest trade group, Pharmaceutical Research and Manufacturers of America, announced that Stephen J. Ubl will be the next president and chief executive officer.

Developed by Inovio Pharmaceuticals, the vaccine has shown the potential to impact precancerous cervical lesions.

Posters focus on next-generation sequencing ovarian cancer and identify candidates for treatment with PARP inhibitors.

Healthcare groups and members of the Senate Judiciary Committee have weighed in with concerns about decreased competition and harm to consumers if the Aetna-Humana and Anthem-Cigna transactions are approved.

Peter S. Amenta, MD, PhD, spent 8 years as the dean of Rutgers Robert Wood Johnson Medical School during a period of tremendous growth and change.

The trial, conducted in France, was a proof-of-concept study to evaluate the efficacy of targeted agents in patients, based on their tumor's molecular profile.

Innovative trials offer the promise that patients can be treated in their own communities instead of traveling to faraway cancer centers.

Telehealth follow up consultations after a surgical operation have become preferred compared to in-person visits, according to 2 recent studies.

In a letter to Pathway Genomics, the FDA has expressed interest in discussing the company's validation strategy as well as evaluating data on clinical sensitivity and specificity of the CancerIntercept Detect test.

The problem in Kansas is the same as other states without Medicaid expansion: the ACA envisioned universal coverage, and funds to treat the uninsured are dwindling because it was expected that patients who are now in a "gap" would have insurance.

A study published in The Journal of Urology suggests the Grade D recommendation for PSA-based screening may place those with intermediate and high-risk prostate cancer at risk.

The research by the group from Spain is the latest effort to link sleep patterns, or disruption of sleep, to the development of type 2 diabetes.

Public outrage over the 5000% price increase for Daraprim, a 62-year-old drug purchased by Turing Pharmaceuticals in August, prompted the company to promise it would lower the drug's cost. This is not the first time such an incidence has occurred.

A JAMA Internal Medicine study found the terms "breakthrough" and "promising" raised people's expectations on the drug's performance as opposed to when the drugs were described as having met the breakthrough criteria.

Screening in a primary care setting may help managed care plans avoid long-term costs of complications of type 2 diabetes.

Hillary Clinton unveiled a plan in Iowa that features a $250 per month cap on drug costs for patients with chronic conditions. This comes 2 weeks after her chief rival for the Democratic nomination, US Senator Bernie Sanders of Vermont, introduced a bill aimed at reining in drug costs. In the summer, The American Journal of Managed Care said polling showed that rising drug costs were poised to become a major issue in the 2016 campaign.

A 3-year study of 200,000 Cigna customers has revealed just how expensive correctable health conditions can be and not knowing what health conditions they have can cost consumers even more.

A white paper released by QuantiaMD has identified a lack of awareness and education about biosimilars among prescribing physicians.

The federal government intends to modernize the US health information technology (IT) infrastructure so patients, providers, and communities can achieve health and wellness goals.

Lonsurf (TAS-102) is an oral 2-drug combination pill that is intended for metastatic colorectal cancer patients who have failed on chemotherapy and biological therapy.

The research could hold the key to a novel treatment for type 2 diabetes, although it will take years to adapt the idea to clinical practice.

Despite the reported slowdown in healthcare spending, consumers are unlikely to have noticed such a change because of the sharp increase in deductibles.